Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

This multicenter, open-label, randomized phase 2 study assessed the efficacy and safety of pomalidomide (POM) with/without low-dose dexamethasone (LoDEX) in patients with relapsed/refractory multiple myeloma (RRMM). Patients who had received ≥2 prior therapies (including lenalidomide [LEN] and borte...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Richardson, Paul G., Siegel, David S., Vij, Ravi, Hofmeister, Craig C., Baz, Rachid, Jagannath, Sundar, Chen, Christine, Lonial, Sagar, Jakubowiak, Andrzej, Bahlis, Nizar, Song, Kevin, Belch, Andrew, Raje, Noopur, Shustik, Chaim, Lentzsch, Suzanne, Lacy, Martha, Mikhael, Joseph, Matous, Jeffrey, Vesole, David, Chen, Min, Zaki, Mohamed H., Jacques, Christian, Yu, Zhinuan, Anderson, Kenneth C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2014
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3962162/
https://ncbi.nlm.nih.gov/pubmed/24421329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-538835
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak